Simvastatin (Zocor)

Subscribe to Selected New Research on Simvastatin

1679 relevant articles (183 outcomes, 526 trials/studies) found for this Drug

Description: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.

Also Known As:

Zocor; MK-733; Synvinolin; MK 733; MK733

Relationship Network

Drug Context: Research Results

Experts

1.	Pedersen, Terje R: 9 articles (09/2008 - 01/2004)
2.	Kastelein, John J P: 9 articles (04/2008 - 07/2002)
3.	Davidson, Michael H: 7 articles (01/2008 - 12/2002)
4.	Blazing, Michael A: 6 articles (09/2008 - 11/2003)
5.	Oikawa, Shinichi: 6 articles (08/2008 - 12/2002)
6.	Shimamoto, Kazuaki: 6 articles (08/2008 - 12/2002)
7.	Nakaya, Noriaki: 6 articles (08/2008 - 12/2002)
8.	Kita, Toru: 6 articles (08/2008 - 12/2002)
9.	Matsuzaki, Masunori: 6 articles (08/2008 - 12/2002)
10.	Saito, Yasushi: 6 articles (08/2008 - 12/2002)

Related Diseases

1.	Hypercholesterolemia 10/16/1989 - "Simvastatin appears to be an effective and well-tolerated agent for the treatment of primary hypercholesterolemia and, as further study confirms long-term safety and efficacy, it should become a useful addition to the therapeutic armamentarium." 12/01/1999 - "Simvastatin therapy for 12 months is well tolerated and effective for both women and men with hypercholesterolemia" 05/01/1997 - "We found that low-dose simvastatin therapy is effective in achieving long-term decreases in serum lipid levels and is well tolerated by patients with moderate hypercholesterolemia" 11/01/1995 - "They further indicate that once-daily treatment with simvastatin is effective in patients with isolated hypercholesterolemia or hypercholesterolemia associated with elevated triglyceride levels." 08/01/2008 - "CONCLUSIONS: Long-term, low-dose simvastatin therapy was safe and effective in Japanese patients with hypercholesterolemia" Order ALL the reference details at left...
2.	Hyperlipidemias (Hyperlipidemia) 03/01/2004 - "CONCLUSION: Simvastatin was an effective and generally well tolerated treatment for hyperlipidemia when used in combination with TZD therapy in this population of patients with type 2 DM." 05/01/2008 - "This study suggests for the first time that simvastatin treatment in diabetic patients with hyperlipidemia is associated with an improvement in the heterogeneity of cardiac repolarization" 11/01/2002 - "This study shows that plasma hs-CRP concentration can be reduced by 8-week administration of simvastatin in type 2 diabetic patients with hyperlipidemia." 01/15/2001 - "Twenty subjects with mixed hyperlipidemia participated in a 3-arm crossover trial to evaluate the effectiveness of high-dose simvastatin as monotherapy" 03/01/2008 - "And the SOD and GSH-Px activities of serum in the group of HuDan Granules were much higher than those in hyperlipidemia group and the Simvastatin group (P<0.05)" Order ALL the reference details at left...
3.	Coronary Disease (Coronary Heart Disease) 07/01/2008 - "METHODS: A cohort from the United Kingdom General Practice Research Database (GPRD) was used to replicate the Scandinavian Simvastatin Survival Study RCT, which investigated statin treatment of hypercholesterolemic subjects with coronary heart disease" 06/01/2007 - "With the advent of the classic statin-megatrials such as the Scandinavian Simvastatin Survival Study (4S), WOSCOPS, CARE, and the more recent Heart Protection Study (HPS), the role of statins in both the primary and secondary prevention and ultimate risk reduction of patients with coronary disease has been firmly established" 08/01/2004 - "OBJECTIVE: To compare the results of the GOALLS and STATT studies that used similar titrate-to-goal protocols with 20 mg up to 80 mg simvastatin in Asian and non-Asian coronary heart disease (CHD) patients" 08/01/2004 - "Efficacy and safety of simvastatin in Asian and non-Asian coronary heart disease patients: a comparison of the GOALLS and STATT studies." 04/01/2003 - "The Japan Lipid Intervention Trial (J-LIT) study, a nationwide cohort study utilizing the clinical practice of general physicians, was designed to clarify the relationship between the incidence of coronary heart disease and serum lipid concentrations during simvastatin therapy, as well as the safety of the therapy, in a large number of Japanese hypercholesterolemic patients" Order ALL the reference details at left...
4.	Coronary Artery Disease (Coronary Atherosclerosis) 02/01/1997 - "Using 20 mg simvastatin, day-1, a treatment period of up to 4 years was necessary to show a significant reduction in coronary artery disease progression" 11/01/2004 - "Intermittent simvastatin treatment may help to increase compliance and can be a treatment alternative in patients with CRF at risk of coronary artery disease" 07/20/2004 - "Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study." 06/01/2004 - "A randomized, open-label, comparative study of simvastatin plus diet versus diet alone on angiographic retardation of coronary atherosclerosis in adult Japanese patients: Japanese utilization of simvastatin therapy (JUST) study." 01/01/2004 - "The accuracy of the model in projecting the percentage of patients who experience fatal and nonfatal CHD events was assessed by using individual baseline patient characteristics from two long-term outcomes trials: the Air Force Coronary Atherosclerosis Prevention Study, a primary prevention trial, and the Scandinavian Simvastatin Survival Study, a secondary prevention trial" Order ALL the reference details at left...
5.	Atherosclerosis (Atheroma) 05/01/1991 - "The results indicate that simvastatin would be effective in the treatment of atherosclerosis." 02/04/2004 - "The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: in vivo study by high-resolution magnetic resonance imaging." 12/05/2000 - "METHODS AND RESULTS: In the present study, we report that simvastatin reduces endothelial barrier dysfunction, which is associated with the development of atherosclerosis" 10/01/2000 - "OBJECTIVES: The aim of this study was to test the effect of high-dose simvastatin therapy on vascular permeability, a key variable in the atherogenic process, and endothelial-mediated vasodilator responses in patients with hypercholesterolemic atherosclerosis" 07/01/1995 - "The our data, in agreement with those documenting the beneficial effect of Simvastatin in greatly decreasing CH and LDL-CH, but point out the need for further studies concerning the long-ter effect of simvastatin on Lp(a), in order to fully establish its role in the secondary prevention of atherosclerosis." Order ALL the reference details at left...

Related Drugs and Biologics

1.	atorvastatin (Lipitor)
2.	Pravastatin (Pravachol)
3.	Cholesterol
4.	LDL Cholesterol
5.	ezetimibe (Zetia)